Psoriatic Arthritis
📧 Sign up to get email alerts when something new happens for Psoriatic Arthritis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-02-04Clinical Trial Update: A Study of Guselkumab in Participants With Active Psoriatic Arthritis [Phase 3]
Phase 3 clinical trial update for guselkumab in active psoriatic arthritis.
-
CLINICAL_TRIALS trial_result · 2026-02-04Clinical Trial Update: A Study of Guselkumab in Participants With Active Psoriatic Arthritis [Phase 3]
Guselkumab is being studied in a Phase 3 trial for active psoriatic arthritis. The study is currently active but not recruiting, and results…
-
CLINICAL_TRIALS trial_result · 2026-02-04Clinical Trial Update: Upadacitinib Versus IL-17 Inhibitors in Patients With Psoriatic Arthritis
A completed clinical trial comparing upadacitinib with IL-17 inhibitors in patients with psoriatic arthritis.
-
EMA approval · 2026-01-28EMA Authorised: Hukyndra (adalimumab) — Stada Arzneimittel AG
EMA authorised Hukyndra (adalimumab) from Stada Arzneimittel AG for multiple inflammatory diseases, including rheumatoid arthritis, psoriati…
-
EMA approval · 2026-01-28EMA Authorised: Leflunomide Zentiva (previously Leflunomide Winthrop) (leflunomide) — Zentiva k.s.
The EMA has authorised Leflunomide Zentiva for use in rheumatoid arthritis and psoriatic arthritis.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-01-27EMA Authorised: Cimzia (certolizumab pegol) — UCB Pharma
The European Medicines Agency authorised Cimzia (certolizumab pegol) for treatment of rheumatoid arthritis and other inflammatory diseases, …
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: Combined High-Intensity Aerobic Training and Resistance Training in Psoriatic Arthritis [NA]
A clinical trial is evaluating a combined high-intensity aerobic training and resistance training program for psoriatic arthritis, currently…
-
CLINICAL_TRIALS trial_result · 2026-01-21Clinical Trial Update: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight [Phase 3]
Phase 3 trial evaluating the concomitant use of ixekizumab and tirzepatide in adults with psoriatic arthritis who are obese or overweight; t…
-
EMA approval · 2026-01-19EMA Authorised: Skyrizi (risankizumab) — AbbVie Deutschland GmbH & Co. KG
The EMA authorised Skyrizi (risankizumab) for multiple indications. This expands its approved uses to psoriasis, psoriatic arthritis, ulcera…
-
CLINICAL_TRIALS trial_result · 2026-01-16Clinical Trial Update: Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) [Phase 3]
Clinical trial update evaluating the efficacy and safety of tildrakizumab versus placebo in active psoriatic arthritis in a Phase 3 study (I…
-
EMA approval · 2026-01-09EMA Authorised: Usymro (ustekinumab) — Gedeon Richter Plc.
EMA authorised Usymro (ustekinumab) by Gedeon Richter for Crohn's disease, psoriasis, and psoriatic arthritis.
-
CLINICAL_TRIALS trial_result · 2026-01-09Clinical Trial Update: Assessment of Fatigue in Psoriatic Arthritis and Cutaneous Psoriasis Patients [NA]
This clinical trial update notes that the study assessing fatigue in patients with psoriatic arthritis and cutaneous psoriasis has completed…
-
CLINICAL_TRIALS research · 2026-01-09Clinical Trial Update: Skin Autofluorescence Assessment of Advanced Glycation End Products in Rheumatic Diseases
A clinical trial investigating skin autofluorescence as a noninvasive measure of advanced glycation end products across several rheumatic di…
-
CLINICAL_TRIALS research · 2026-01-08Clinical Trial Update: Creating Health Course Study for People With Rheumatological Conditions [NA]
A new health course study for people with rheumatological conditions is currently recruiting, spanning rheumatoid arthritis, Sjögren's syndr…
-
FDA approval · 2026-01-07FDA Approved: YESINTEK — Supplemental Application (Biocon Biologics Inc.)
The FDA approved a supplemental application for YESINTEK (ustekinumab) from Biocon Biologics Inc. The action relates to the ustekinumab bios…
-
CLINICAL_TRIALS trial_result · 2026-01-07Clinical Trial Update: Activating the Cholinergic Anti-Inflammatory Pathway in Healthy Volunteers and People With Inflammatory Arthritis [NA]
A completed clinical trial update from Surf Therapeutics examining activation of the cholinergic anti-inflammatory pathway in healthy volunt…
-
CLINICAL_TRIALS trial_result · 2025-12-31Clinical Trial Update: Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjects [Phase 1]
A Phase 1 study comparing pharmacokinetics and safety of Celltrion's CT-P52 against US-licensed ixekizumab (Taltz) in healthy participants.
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases
A clinical trial update indicates a study assessing the effects of phytocannabinoids on immune response and autophagy in chronic immune-medi…
-
FDA approval · 2025-12-23FDA Approved: OTEZLA — Supplemental Application (Amgen, Inc)
FDA approved a supplemental application for OTEZLA (apremilast) from Amgen, Inc. The approval updates the labeling for the product.
-
CLINICAL_TRIALS research · 2025-12-23Clinical Trial Update: Physician- vs Questionnaire-Based Screening for Psoriatic Arthritis in Psoriasis
The clinical trial NCT07298265 evaluating physician- versus questionnaire-based screening for psoriatic arthritis in psoriasis patients is c…
-
EMA approval · 2025-12-18EMA Authorised: Cosentyx (secukinumab) — Novartis Europharm Limited
The EMA authorised Cosentyx (secukinumab) for psoriatic arthritis, psoriasis, and ankylosing spondylitis.
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis [Phase 2]
A Phase 2 trial for targeted therapies to treat active psoriatic arthritis is currently recruiting.
-
EMA approval · 2025-12-16EMA Authorised: Erelzi (etanercept) — Sandoz GmbH
The EMA authorised Erelzi (etanercept) by Sandoz GmbH as a biosimilar to treat several inflammatory conditions including rheumatoid arthriti…
-
EMA approval · 2025-12-15EMA Authorised: Remicade (infliximab) — Janssen Cilag International NV
The EMA has authorised Remicade (infliximab) for multiple inflammatory diseases under Janssen Cilag International NV as the marketing author…
-
EMA approval · 2025-12-11EMA Authorised: Hyrimoz (adalimumab) — Sandoz GmbH
EMA authorised Hyrimoz (adalimumab) by Sandoz GmbH as a biosimilar to Humira for multiple inflammatory diseases, including rheumatoid arthri…